Significant difference in gut microbiota Bifidobacterium species but not Lactobacillus species in colorectal cancer patients in comparison with healthy volunteers using quantitative real-time PCR.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Colorectal Neoplasms*/microbiology ; Colorectal Neoplasms*/genetics ; Bifidobacterium*/genetics ; Bifidobacterium*/isolation & purification ; Lactobacillus*/genetics ; Lactobacillus*/isolation & purification ; Gastrointestinal Microbiome*/genetics ; Real-Time Polymerase Chain Reaction* ; Feces*/microbiology; Humans ; Male ; Female ; Middle Aged ; Aged ; Healthy Volunteers ; Case-Control Studies ; Adult ; DNA, Bacterial/genetics ; RNA, Ribosomal, 16S/genetics ; Probiotics
    • Abstract:
      Background: Colorectal cancer (CRC), with a growing incidence trend, is one of the most diagnosed cancers and the second cause of cancer-related deaths worldwide. The literature has frequently focused attention on the correlation between the gut microbiota imbalance and CRC. The genera Lactobacillus and Bifidobacterium have recently received increasing attention because of their potential in restoring alterations in the gut microflora. Therefore, this study aimed to quantitatively evaluate the presence of lactobacilli and bifidobacterial strains in the fecal samples of CRC patients compared to healthy volunteers.
      Methods: From 2018 to 2019, 25 confirmed CRC patients and 25 age- and gender-matched control subjects were enrolled in the study. Bacterial DNA was extracted from the fecal samples and the presence of lactobacilli and bifidobacterial strains were quantitatively determined using quantitative real-time PCR using genus-specific 16S rDNA primers.
      Results: A significant decline in the abundance of bifidobacteria in CRC patients compared to healthy individuals (p value<0.003) was observed; however, no significant difference was observed between the two groups regarding the abundance of lactobacilli (p value<0.163). Correlation analysis showed a positive association between the lack of genetic history of CRC and the numbers of gut bifidobacteria and lactobacilli.
      Conclusion: As a putative gut probiotic, depletion of bifidobacteria showed significant correlation to the development and progression of CRC; therefore, therapeutic use of these probiotic bacteria could be considered a possible adjuvant approach in disease management through modulation of the microbiota.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2024 Esfandiari et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Cancer Cell. 2018 Jun 11;33(6):954-964. (PMID: 29657127)
      Nature. 2014 Oct 23;514(7523):508-12. (PMID: 25174708)
      Science. 2015 Nov 27;350(6264):1084-9. (PMID: 26541606)
      Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5. (PMID: 16033867)
      CA Cancer J Clin. 2001 Jan-Feb;51(1):38-75; quiz 77-80. (PMID: 11577479)
      Int J Food Microbiol. 2008 Dec 10;128(2):219-25. (PMID: 18809220)
      Mol Biol Rep. 2010 Mar;37(3):1373-6. (PMID: 19330535)
      FEMS Microbiol Ecol. 2009 Aug;69(2):213-21. (PMID: 19496818)
      ISME J. 2013 Jul;7(7):1256-61. (PMID: 23677008)
      Oncotarget. 2017 May 2;8(18):30563-30575. (PMID: 28430644)
      Gut. 2013 Apr;62(4):531-9. (PMID: 22993202)
      Nat Microbiol. 2018 Nov;3(11):1255-1265. (PMID: 30349083)
      Int J Cancer. 2009 May 15;124(10):2406-15. (PMID: 19142968)
      Biol Psychiatry. 2015 Apr 1;77(7):607-15. (PMID: 25173628)
      PLoS One. 2013 Aug 14;8(8):e70955. (PMID: 23967140)
      Sci Rep. 2018 Sep 18;8(1):13974. (PMID: 30228361)
      Gastroenterol Hepatol (N Y). 2013 Sep;9(9):560-9. (PMID: 24729765)
      Nutr Cancer. 2005;51(1):102-9. (PMID: 15749636)
      Nature. 2006 Dec 21;444(7122):1027-31. (PMID: 17183312)
      Front Immunol. 2017 Nov 17;8:1553. (PMID: 29209314)
      Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):198-205. (PMID: 25342387)
      Int J Mol Sci. 2015 Apr 02;16(4):7493-519. (PMID: 25849657)
      Gastroenterol Hepatol Bed Bench. 2018 Spring;11(2):101-109. (PMID: 29910850)
      J Cancer Educ. 2017 Sep;32(3):447-453. (PMID: 26700179)
      Curr Top Microbiol Immunol. 2013;358:273-89. (PMID: 22476557)
      Pediatrics. 2010 Jan;125 Suppl 1:S1-18. (PMID: 20048083)
      PLoS One. 2011 Jan 27;6(1):e16393. (PMID: 21297998)
      Nat Med. 2019 Mar;25(3):377-388. (PMID: 30842679)
      Am J Hum Genet. 2008 Mar;82(3):631-40. (PMID: 18313023)
      Microorganisms. 2021 Jul 21;9(8):. (PMID: 34442626)
      Cancer J. 2014 May-Jun;20(3):217-24. (PMID: 24855011)
      Gastroenterology. 2013 Jun;144(7):1394-401, 1401.e1-4. (PMID: 23474283)
      Cancer Res. 1997 Nov 1;57(21):4787-94. (PMID: 9354440)
      Cancers (Basel). 2020 May 29;12(6):. (PMID: 32486066)
      Nature. 2008 Oct 23;455(7216):1109-13. (PMID: 18806780)
      Clin Colon Rectal Surg. 2018 May;31(3):192-198. (PMID: 29720905)
      BMC Cancer. 2018 Dec 7;18(1):1227. (PMID: 30526552)
      Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. (PMID: 12900694)
      Am J Clin Nutr. 2013 Jan;97(1):117-26. (PMID: 23235200)
      Evid Based Complement Alternat Med. 2020 Feb 14;2020:3535982. (PMID: 32148539)
      Int J Colorectal Dis. 2015 Dec;30(12):1653-7. (PMID: 26358068)
      Gastroenterology. 2009 Nov;137(5):1716-24.e1-2. (PMID: 19706296)
      Prz Gastroenterol. 2019;14(2):89-103. (PMID: 31616522)
      Mayo Clin Proc. 2019 Jun;94(6):1099-1116. (PMID: 31171120)
      J Nutr. 2007 Jan;137(1 Suppl):175S-182S. (PMID: 17182822)
      Cell Host Microbe. 2008 Apr 17;3(4):213-23. (PMID: 18407065)
      Gut. 2017 Apr;66(4):683-691. (PMID: 26818619)
      Gut. 2013 Jun;62(6):812-23. (PMID: 23408351)
      Cancer Discov. 2013 Apr;3(4):384-7. (PMID: 23580283)
      Front Immunol. 2020 Nov 30;11:615056. (PMID: 33329610)
      mBio. 2013 Nov 05;4(6):e00692-13. (PMID: 24194538)
      J Mol Diagn. 2021 Nov;23(11):1452-1459. (PMID: 34454113)
      Oncoscience. 2014 Jun 30;1(6):400-6. (PMID: 25594038)
      Obes Rev. 2018 Jan;19(1):62-80. (PMID: 29024387)
      World J Gastroenterol. 2016 Jan 14;22(2):501-18. (PMID: 26811603)
      Microb Pathog. 2017 Oct;111:362-369. (PMID: 28912092)
      Anal Biochem. 2019 Oct 15;583:113363. (PMID: 31310737)
      Am J Clin Nutr. 2007 Feb;85(2):488-96. (PMID: 17284748)
      Gastroenterology Res. 2018 Aug;11(4):264-273. (PMID: 30116425)
      ISME J. 2011 Jan;5(1):82-91. (PMID: 20613793)
      CA Cancer J Clin. 2020 May;70(3):145-164. (PMID: 32133645)
      Mediators Inflamm. 2018 Apr 2;2018:8168717. (PMID: 29805314)
      New Microbes New Infect. 2021 Feb 02;41:100845. (PMID: 34035924)
      N Engl J Med. 1994 Dec 22;331(25):1669-74. (PMID: 7969357)
      Lancet. 2015 Nov 14;386(10007):1945-1954. (PMID: 26386538)
      PLoS One. 2010 Feb 05;5(2):e9085. (PMID: 20140211)
      J Oncol. 2019 Feb 21;2019:4315032. (PMID: 30915121)
      Br J Cancer. 2015 Feb 3;112(3):580-93. (PMID: 25422909)
    • Accession Number:
      0 (DNA, Bacterial)
      0 (RNA, Ribosomal, 16S)
    • Publication Date:
      Date Created: 20241127 Date Completed: 20241127 Latest Revision: 20241130
    • Publication Date:
      20241202
    • Accession Number:
      PMC11602092
    • Accession Number:
      10.1371/journal.pone.0294053
    • Accession Number:
      39602380